IVI in the Media
Intravacc and IVI are partnering for Vaccine Research and Development for Developing Countries
The collaboration will focus on improving available technologies for vaccine development and in addition on the clinical evaluation and the regulatory process. The two parties will work together to create a joint application for funding of a collaborative project. They will also join forces on further development and complement training initiatives in vaccinology for developing countries, including a possible laboratory-oriented course.
Millennium Development Goals
“Intravacc has an extensive history in developing and improving vaccines while IVI has excellent knowledge in facilitating the introduction of sustainable vaccines in countries where vaccines are most needed,” says Gisella Frijlink, CEO of Intravacc. “By joining forces, Intravacc and IVI will contribute to Millennium Development Goal #8, which aims to develop a global partnership for development.”
Intravacc moves good ideas from science a step further on the path to valuable vaccines for both public health and industry. According to Intravacc’s vision, a lasting collaboration between public and private institutes with shared goals is important for long-term worldwide improvement of human health.
IVI is an independent international organization headquartered in Seoul, South Korea. IVI’s mission is to discover, develop, and deliver safe, effective, and affordable vaccines for developing nations. The Netherlands is among 36 signatories signed to IVI’s Establishment Agreement, which also includes South Korea and the World Health Organization.
“As a signatory country of IVI, the Netherlands has been an important supporter of the organization,” says Dr. Christian Loucq, IVI’s Director General. “This partnership will benefit both Intravacc and IVI in that it furthers our mutual aim to ensure that vaccines are developed and made available to the poor, and in how it deepens our relationship with the Netherlands, a key IVI partner.”
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 36 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.
Intravacc (Institute for Translational Vaccinology) works under the Ministry of Public Health, Welfare and Sport. It is the place in the Netherlands with a widely accessible and complete infrastructure for translational vaccine research and development. The available knowledge in the field of vaccine development and production can be applied to R&D projects for customers. Typical clients of Intravacc are various companies, governments and other public institutions. (www.intravacc.nl)
IVI Media Contact:
Tae Kyung Byun
Public Awareness / Advocacy Officer